**JETREA® (ocriplasmin) injection, for Intravitreal Injection, 1.25 mg/mL**

**Preparation and Administration for Already Diluted Formulation**

**DO NOT** discard packaging until JETREA has been removed from the shipper

**PLEASE READ ALL INSTRUCTIONS BELOW BEFORE REMOVING CONTENTS**

**Note:** Each shipping box holds 1 to 12 cartons of JETREA (ocriplasmin) injection, for Intravitreal Injection, 1.25 mg/mL.

**JETREA CARTONS**

- **Contents:** JETREA contained in plastic bags with dry ice
- **Instructions:** Remove JETREA from the dry ice in the bottom polystyrene compartment and store immediately in a -4°F (-20°C) freezer.
- **Protect the vials from light by storing in the original package until time of use.

**CAUTION**

- Dry ice (solid carbon dioxide) is extremely cold and can cause frostbite—use insulated gloves when removing the JETREA cartons. **Note:** Gloves are not provided in this container.
- Solid dry ice converts directly to gas over time; vapor accumulation can cause suffocation at elevated levels. Handle dry ice in a well-ventilated area only.
- Do not transport the shipping box with dry ice in enclosed vehicles, as carbon dioxide vapor will accumulate and cause suffocation.
- To dispose of the dry ice, leave it in the shipping container in a well-ventilated area not accessible to children, and it will evaporate naturally over time.
- If no dry ice is visible when you open the package upon receipt, do not use the product and contact the supplier.

**See reverse side for Preparation and Administration instructions**

©2017 ThromboGenics, Inc. All rights reserved.
ThromboGenics, Inc., 101 Wood Avenue South, Suite 610, Iselin, NJ 08830 - USA

JETREA and the JETREA logo and THROMBOGENICS and the THROMBOGENICS logo are trademarks or registered trademarks of ThromboGenics NV.

www.jetrea.com
**Important: Post-Injection Instructions**

- Immediately following the intravitreal injection, patients should be monitored for elevation in intraocular pressure.
- Patients should be instructed to immediately report any symptoms following the injection (e.g., eye pain, redness of the eye, photophobia, blurred or decreased vision).
- Each vial should only be used to provide a single injection for the treatment of a single eye. If the contralateral eye requires treatment, a new vial should be used, however, treatment with JETREA in the other eye is not recommended within 7 days of the initial injection in order to monitor the post-injection course in the injected eye.
- Repeated administration of JETREA in the same eye is not recommended.
- No special dosage modification is required for any of the populations that have been studied (e.g., gender, elderly).

**Important Safety Information**

**Warnings and Precautions**

- A decrease of ≥ 3 lines of best-corrected visual acuity (BCVA) was experienced by 5.6% of patients treated with JETREA and 3.2% of patients treated with vehicle in the controlled trials. The majority of these decreases in vision were due to progression of the condition with traction and many required surgical intervention. Patients should be monitored appropriately.

**Adverse Reactions**

- The most commonly reported reactions (≥ 5%) in patients treated with JETREA were vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, and retinal edema.

**Please see additional Important Safety Information and full Prescribing Information enclosed.**